DM001 / Doma Pharma, Biocytogen - LARVOL DELTA

A Study of DM001 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=128 | Recruiting | Sponsor: Xadcera Biopharmaceutical (Suzhou) Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Doma Pharmaceuticals' DM001 bispecific ADC has obtained FDA IND approval and is about to start Phase I clinical trials [Google translation] (Sohu.com) - "On July 4, 2024, the first bispecific ADC product of Doma Pharmaceuticals (and its subsidiary Sidao Pharmaceuticals), DM001, was officially approved by the US FDA IND. On June 26, 2024, it was also officially approved by the Australian CTN and is about to start Phase I clinical research."

IND • Trial status • Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Study of DM001 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=128 | Not yet recruiting | Sponsor: Xadcera Biopharmaceutical (Suzhou) Co., Ltd.

Metastases • New P1 trial • Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

DM001: A novel bispecific ADC targeting TROP2 and EGFR with potent anti-tumor efficacy in PDX models (SITC 2023) - "Notably, DM001 efficacy was superior to parental ADCs in patient-derived lung and pancreatic xenograft models. Conclusions DM001 is a novel, first-in-class bispecific ADC targeting EGFR and TROP2 that demonstrates in vivo efficacy against a variety of cell and patient-derived tumors."

Clinical • Oncology • Solid Tumor • EGFR • TACSTD2

Biocytogen Announces 16 Poster Presentations and Booth Exhibition at SITC 2023 (Businesswire) - "Biocytogen Pharmaceuticals (Beijing) Co., Ltd...announced today that the company will be presenting 16 posters and exhibiting at booth 223 at the Society for Immunotherapy of Cancer (SITC) annual conference, taking place from November 1-5, 2023 in San Diego, CA."

Preclinical • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

A first-in-class anti-TROP2/EGFR bispecific antibody-drug conjugate, DM001, exhibits potent anti-tumor efficacy (AACR 2023) - "Interestingly, the efficacy of DM001 was superior to its parental ADCs in BP0508 lung cancer and BP0209 pancreatic cancer PDX models, but not obvious in Panc.02.03 CDX models, indicating that DM001 may effectively target heterogeneous tumors, which better mimic the tumor microenvironment in patients. In summary, DM001 is a novel bispecific ADC with promising therapeutic potential that can be further exploited to treat TROP2 and EGFR co-expressing tumors."

Clinical • Late-breaking abstract • Gastrointestinal Cancer • Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • TACSTD2